Moe Alsumidaie

http://Moe%20Alsumidaie
Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.

Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression

The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Interview with Veeva’s Richard Young

  • By Moe Alsumidaie
  • September 9, 2024

Previous post
Integrating QBD and RBM Approaches in Clinical Trials
Next post
Interview with Veeva’s Rylan Collins

Latest News

  • Phase IV heart failure studies use digital tools to address patient dropout from low perceived benefit 01
    News

    Phase IV heart failure studies use digital tools to address patient dropout from low perceived benefit

    October 14, 2026
  • CRIO Launches AI eSource Builder to Cut Protocol Review Time by Four Hours 02
    News

    CRIO Launches AI eSource Builder to Cut Protocol Review Time by Four Hours

    October 14, 2026
  • Senti Biosciences Adjourns Merger Vote, Seeking Additional Stockholder Support 03
    News

    Senti Biosciences Adjourns Merger Vote, Seeking Additional Stockholder Support

    October 14, 2026
  • Phio Pharmaceuticals Completes Commercial cGMP Batch of PH-762 04
    News

    Phio Pharmaceuticals Completes Commercial cGMP Batch of PH-762

    October 14, 2026
  • ArriVent doses first patient with ARR-002 dual-target ADC for ovarian cancer 05
    News

    ArriVent doses first patient with ARR-002 dual-target ADC for ovarian cancer

    October 14, 2026
  • Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease 06
    News

    Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease

    October 14, 2026
The Clinical Trial Vanguard
  • ABOUT US
  • Log In
  • Membership Account
    • Membership Billing
    • Membership Cancel
    • Membership Orders
    • Your Profile
  • Membership Checkout
    • Membership Confirmation
  • Membership Levels
  • PRIVACY POLICY
  • SUBSCRIBE
  • TERMS AND CONDITIONS OF ACCESS AND USE
Copyright © 2026 The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Start typing and press Enter to search

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}